UNICEF analysis indicates that:
- Investments that increase access to high-impact health and nutrition interventions by poor groups have saved almost twice as many lives as equivalent investments in non-poor groups.
- Access to high-impact health and nutrition interventions has improved ra...pidly among poor groups in recent years, leading to substantial improvements in equity.
- During the period studied, absolute reductions in under-five mortality rates associated with improvements in intervention coverage were three times faster among poor groups than non-poor groups.
- Because birth rates were higher among the poor, the reduction in the under-five mortality rate translated into 4.2 times more lives saved for every 1 million people. Indeed, of the 1.1 million lives saved across the 51 countries during the final year studied for each country, nearly 85 per cent were among the poor.
- Intensified focus on equity-enhancing policies and investments can help countries achieve the Sustainable Development Goal newborn and child mortality targets (SDG3.2).
more
This Technical Brief reviews current practice and evidence on nutrition-specific preventive approaches to MAM, providing practical guidance for implementers and programme managers, and highlighting gaps in evidence and guidance.
This document was conducted as a desk study and provides useful information and practical examples of responses to HIV and AIDS in the fields of agriculture, rural development, self-help and social protection. It aims to invite Misereor partners and others working in these fields to reflect on their... current approaches and to encourage them to respond, in their core business, to the challenges presented by HIV and AIDS.
more
The 2016-2017 Biennial report presents an overview of WHO Namibia's main achievements and challenges and highlights its vision for the next five years.
Review
www.co-hivandaids.com
Volume 12 Number 4 July 2017
Web annex 6: Injectable prostaglandins versus
placebo or no treatment
Evidence to Decision Framework
Expanding access to quality health services through task sharing
Co-trimoxazole is a fixed-dose combination of two antimicrobial drugs (sulfamethoxazole and trimethoprim) that covers a variety of bacterial, fungal and protozoan infections. Co-trimoxazole preventive therapy is a feasible, well tolerated and inexpensive intervention for people living with HIV to re...duce HIV-related morbidity and mortality. Further, co-trimoxazole is an off-patent drug and widely available in resource-limited settings.
more
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
As the COVID-19 pandemic continues to threaten health and food systems around the world, the 2020 Global Nutrition Report calls on governments, businesses and civil society to step up efforts to address malnutrition in all its forms.
Web annex 5: Oxytocin and ergometrine versus placebo or no treatment
Evidence to decision framework
National Statistical Committee of the Kyrgyz Republic Bishkek, Kyrgyz Republic
Ministry of Health Bishkek, Kyrgyz Republic
MEASURE DHS
ICF International Calverton, Maryland, U.S.A.
Adapted from the WHO's Decision-Making Tool for family
planning clients and providers